AbbVie Inc. (NYSE:ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescription drug prices and comply with additional policy demands from President Donald Trump.

Reuters on Tuesday highlighted that around five companies are expected to be included in the initial announcement.

In September, Pfizer Inc. (NYSE:PFE) announced the first agreement with the Trump Administration to ensure U.S. patients pay lower prices for their prescription medicines.

The administration is also set to outline a pilot program that would link Medicare drug payments to the lowest prices charged by manufacturers in a group of comparable foreign markets.

Also Read: AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report

Who Is Cutting Deals?

In July, Trump sent letters to 17 major pharmaceutical companies calling for "most-favored-nation" pricing for Medicaid, limits on U.S. launch prices relative to other high-income countries, increased domestic reinvestment, and expanded direct-to-consumer sales models.

Five companies—Pfizer, Eli Lilly and Co